A5076393863- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Blood groups and transfusion
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Galectins and Cancer Biology
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Erythrocyte Function and Pathophysiology
- Complement system in diseases
- Genetic factors in colorectal cancer
- CAR-T cell therapy research
- Streptococcal Infections and Treatments
- Protein Tyrosine Phosphatases
- Inflammatory Myopathies and Dermatomyositis
- Cutaneous lymphoproliferative disorders research
- Research on Leishmaniasis Studies
- Musculoskeletal synovial abnormalities and treatments
- Sarcoma Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
Université de Reims Champagne-Ardenne
2016-2025
Centre Hospitalier Universitaire de Reims
2016-2025
Hôpital Robert-Debré
2015-2024
Inserm
2014-2023
Equipe de Recherche en Epidémiologie Nutritionnelle
2014-2023
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2023
Association pour la Recherche en Physiologie de l’Environnement
2014-2020
Creative Commons
2017
Alexion Pharma (Switzerland)
2017
Université Paris Cité
2014-2017
Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL who received developed AF. Median time to onset was 3·8 months. AF persistent 35/56 (62%) cases despite treatment. Clinical included: three episodes severe cardiac failure (one fatal) one stroke; eight non-thrombocytopenic (14%) experienced bleeding adverse events. Altogether,...
Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). We characterize 58 primary human RS samples by genome-wide DNA methylation and whole-transcriptome profiling. Our comprehensive approach determines profile unravels a CLL epigenetic imprint, allowing CLL-RS clonal relationship assessment without need initial tumor DNA. methylation- transcriptomic-based classifiers were developed,...
Histological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 L265P mutation on transformation. We examined risk factors and outcomes associated WM, highlighting role mutation. Patients WM seen at Mayo Clinic, Rochester, USA University Hospital Reims, France, between 01/01/1996 December 31, 2017 were included; 50 (4.3%) 1147 patients transformed to a high-grade lymphoma, median...
We report our experience on bendamustine and rituximab (BR) combination in 26 patients with chronic lymphocytic leukemia (CLL) complicated by autoimmune hemolytic anemia (AIHA). At the time of BR initiation, 88% had already been treated for AIHA CLL was progressive regardless all but one. Overall response rates were 81% 77% CLL. Median to next treatment 28.3 months 26.2 CLL, respectively. therapy may represent a good safe therapeutic option this setting where adequate control seems important...
Purpose The high-dose methotrexate (HD-MTX) regimen (>1 g/m 2 ) is the standard of care for preventing and managing central nervous system (CNS) invasion in diffuse large B-cell lymphoma (DLBCL). Delayed elimination HD-MTX can lead to severe toxicity. Albumin a suggested biological marker predict delayed elimination. This study aims evaluate whether serum albumin be used as predictive factor. Methods retrospective bicentric includes DLBCL patients, receiving from 06.30.2016 12.31.2023...
Abstract Background New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead treatment discontinuation. Preclinical studies reported early severe ocular damage related the use of belantamab mafodotin (belamaf), including surface inflammation, dry eye, and a specific toxicity cornea, namely microcystic keratopathy. While belamaf-induced changes have not been prospectively studied, better understanding mechanisms involved as well...
Abstract We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) France, after a maximum follow-up five years. Patients were included according French marketing authorization 2016 (i.e. relapsed or refractory CLL previously untreated deletion 17p and/or tumor protein p53 mutations unsuitable for chemoimmunotherapy) could have initiated more than 30 days prior their enrolment retrospective...
This study investigated Raman spectroscopy and supervised classification for CLL diagnosis.
Chronic Lymphocytic Leukemia (CLL) is a heterogeneous B cell neoplasm ranging from indolent to rapidly progressive disease. Leukemic subsets with regulatory properties evade immune clearance; however, the contribution of such during CLL progression not completely elucidated. Here, we report that cells crosstalk their counterparts, notably by promoting T (Treg) compartment and shaping several helper (Th) subsets. Among various constitutively- BCR/CD40-mediated factors secreted, tumour...
Only a minority of chronic lymphocytic leukemia (CLL) patients harboring positive direct antiglobulin test (DAT) will develop autoimmune hemolytic anemia (AIHA). In single institution cohort 378 CLL patients, 56 (14.8%) had at least one DAT during the course disease, either diagnosis or later. We found no relationship between time first and overall survival (OS). However, with who did not AIHA same adverse outcome as developed AIHA. Of were in Binet stage A diagnosis, those significantly...
The rare descriptions, in the literature, of ocular infections due to Pasteurella multocida include: endophtalmitis, keratitis and corneal ulcers, Parinaud's oculoglandular syndrome, conjunctivitis. Here, we report a case rapidly evolving conjunctivitis multocida, occurring after direct inoculation with animal droplets an immuno-compromised host.A 69-year-old, Caucasian male was referred our department purulent conjunctivitis, five days chemotherapy for angioimmunoblastic-T-cell-lymphoma,...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma. The prevalence hypercalcemia in this neoplasm and its prognostic significance unclear. We retrospectively evaluated the at diagnosis DLBCL explored associations with clinical factors outcome. Outcome was assessed using event-free survival 24 months (EFS24). A total 305 patients (248 de novo 57 transformed indolent lymphomas) diagnosed between 2006 2018 Reims were analyzed. calcemia >10.5 mg/dL lymphomas 23%...
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) untreated RT of diffuse large B-cell histology (NCT03931642). In this multicentre phase 2 study, without complete response (CR) two cycles were eligible to receive 8-week induction via continuous vein infusion stepwise...
Abstract Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d after failure of all conventional treatments.